Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INFANT BACTERIAL THERAPEUTICS AB (PUBL)

(IBT B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Infant Bacterial Therapeutics : Annual General Meeting of Infant Bacterial Therapeutics CEO speech

05/06/2021 | 12:50pm EDT

CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish.

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com

Attachment

  • PR 20210504 AGM ENG video

© OMX, source GlobeNewswire - EU Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
BIOGAIA AB (PUBL) 2.06% 471.5 Delayed Quote.-12.20%
INFANT BACTERIAL THERAPEUTICS AB (PUBL) -0.39% 76.6 Delayed Quote.-31.61%
All news about INFANT BACTERIAL THERAPEUTICS AB (PUBL)
09/13INFANT BACTERIAL THERAPEUTICS : announces that a new patent is granted in Mexico
AQ
09/10INFANT BACTERIAL THERAPEUTICS : today announces that a new patent is granted in ..
AQ
09/10Infant Bacterial Therapeutics Announces the Mexican Patent Office Grants New ..
CI
08/25INFANT BACTERIAL THERAPEUTICS : Recruitment of the smallest infants in the Conne..
AQ
08/25Infant Bacterial Therapeutics AB Announces Recruitment of the Smallest Infant..
CI
08/16INFANT BACTERIAL THERAPEUTICS AB : (publ) Interim Management Statement, January ..
AQ
08/13INFANT BACTERIAL THERAPEUTICS AB : (publ) Interim Management Statement,áJanuary ..
AQ
08/13Infant Bacterial Therapeutics AB Publ Reports Earnings Results for the Second..
CI
08/13Infant Bacterial Therapeutics AB Announces Interim Management Statement for t..
CI
07/13INFANT BACTERIAL THERAPEUTICS AB : appoints Marie-Louise Alamaa as new CFO
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -72,0 M -8,28 M -8,28 M
Net cash 2020 423 M 48,7 M 48,7 M
P/E ratio 2020 -17,5x
Yield 2020 -
Capitalization 860 M 99,0 M 98,8 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 8
Free-Float 89,2%
Chart INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Duration : Period :
Infant Bacterial Therapeutics AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Staffan Str÷mberg Chief Executive Officer
Marie-Louise Alamaa Chief Financial Officer
Peter Michael Rothschild Chairman
Eamonn Connolly Chief Scientific Officer
Jonas Rastad Chief Medical Officer